FDA Approves New Hemophilia A Drug
The FDA has approved emicizumab-kxwh as prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A...
Emicizumab Prophylaxis Reduces Bleeding Events in Hemophilia A Without Inhibitors
Treatment with emicizumab was associated with lower bleeding rates, compared with no prophylaxis, in patients with hemophilia A without inhibitors, according to findings from...
No Added Benefit When Hydroxyurea Is Combined With Aspirin in Middle-Aged Patients With Essential...
Cytoreductive treatment with hydroxyurea has been shown to reduce the risk of thrombosis in patients with essential thrombocythemia (ET) and high-risk features, which include...
FDA Approves New Treatment for Hemophilia
The U.S. Food and Drug Administration (FDA) approved BAY94-9027, or antihemophilic factor (recombinant), PEGylated-aucl, for the prophylactic treatment of adults and adolescents (≥12 years)...
Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis
Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...
How to Treat Anemia in a Patient Who Refuses Transfusions for Religious Reasons
This month, Neil A. Zakai, MD, discusses how to treat anemia in a patient who refuses packed red blood cells.
And don't forget to check out...
How to Treat Anemia in a Patient Who Refuses Transfusions for Religious Reasons
Here’s how readers responded to a You Make the Call question about a Jehovah's Witness patient with stage IV uterine cancer, a uterine abscess,...
Mapping Silent Cerebral Infarcts in Children With Sickle Cell Anemia
Children with sickle cell anemia (SCA) are at risk of developing cerebral ischemia, including a high prevalence of silent cerebral infarcts (SCI), which can...
LentiGlobin Gene Therapy Possibly Safe for Severe Sickle Cell Disease
Interim data from a phase I study of LentiGlobin BB305 in patients with severe sickle cell disease (SCD) suggest that the gene therapy was...
Breakthroughs in Gene Therapy for Hemophilia
Gene therapy for hemophilia is here – and it’s working. The field is advancing at a steady clip: Results from recent trials of this...
Current Issue
December 2018, Volume 4, Issue 14
This issue features a look at the consequences of medical errors, an update on the Cancer Moonshot Initiative, a preview of 2018 ASH Annual Meeting, and more.
